Objectives: To evaluate the performance of a rapid antimicrobial susceptibility testing (AST) platform based on microfluidic chip technology, the QMAC-dRAST, which enables AST from colony isolates or positive blood culture broth (PBCB), and to compare the performance of the QMAC-dRAST for staphylococci and enterococci with that of the VITEK-2 system based on reference broth microdilution (BMD).
Introduction
Recent advances have been made in pathogen identification methods, such as MALDI-TOF MS and a variety of PCR-based assays. [1] [2] [3] While these assays have decreased the time required for pathogen identification, conventional antimicrobial susceptibility testing (AST) can take up to 24 h, since conventional AST systems detect changes in bacterial populations by measuring the optical density, and massive proliferation is needed to reach a detectable growth level. 4, 5 More rapid AST methods are crucial for effective treatment with narrow-spectrum targeted antibiotics within the same working day of identification. Recently, new phenotypic ASTs have been developed to reduce turnaround time by using high-throughput microfluidic technologies to monitor bacterial morphology. [6] [7] [8] The QMAC-dRAST (QuantaMatrix, Seoul, Republic of Korea) is an AST platform based on microfluidic chip technology to observe changes in single cells under antibiotics. 9 This system enables AST not only from colony isolates, but also directly from positive blood culture broth (PBCB) without a bacteria-separating process. 9 The aim of this prospective study is to compare the performance of the QMAC-dRAST GP (Gram-positive) kit with that of the widely used commercial automated AST, the VITEK-2 system (bioMérieux, Marcy-l'Étoile, France), based on reference broth microdilution (BMD). We included staphylococcal and enterococcal clinical isolates from positive blood culture bottles and subcultured colony isolates.
Materials and methods

Study design and bacterial isolates
This study was conducted at a tertiary-care hospital in Seoul, South Korea. In total, 102 staphylococci-or enterococci-positive blood cultures were non-selectively collected from patients with bloodstream infections between April 2016 and July 2017. In addition, eight blood culture samples artificially spiked with linezolid-resistant enterococci were used. Specimens with streptococci, Gram-negative organisms, fungi, or multiple organisms were excluded from this study.
Ethics
This study was approved by the Institutional Review Board of Samsung Medical Center (approval number: 2016-01-102). The requirement for informed consent was waived.
Identification and susceptibility testing
Blood culture bottles using FAN Plus (bioMérieux) were incubated in the BacT/ALERT 3D system. Organism identification was determined by the VITEK-MS or VITEK-2 identification systems (bioMérieux). MICs were obtained by four different methods: the QMAC-dRAST with two types of inoculum (PBCB and colony isolates); the VITEK-2 system (AST-P600 card for enterococci or AST-P601 card for staphylococci) using software version 7.01; and the BMD test. Once a blood culture was identified as positive, the PBCB was directly used for the QMAC-dRAST. This was followed by subculture on a blood agar plate and incubation overnight at 35 C. Subcultured colony isolates were used for the QMAC-dRAST, VITEK-2 system and BMD tests, which were performed in parallel. The CLSI 2016 breakpoints were used to interpret results, except for fusidic acid, for which the EUCAST breakpoint criteria were applied (Table S1 , available as Supplementary data at JAC Online).
10,11
QMAC-dRAST with PBCB
A sample was collected from PBCB using a syringe. A 10 lL sample of the drawn culture was mixed with 4 mL of liquid-state 0.5% agarose at 37-40 C. Then, 10 lL of the mixture was inoculated into each radial-shaped chamber of a 96-well format QMAC-dRAST GP panel containing freeze-dried antimicrobial agents at several concentrations. 9 After solidifying the inoculated mixture at room temperature, 100 lL of CAMHB was added to the satellite well of each chamber to rehydrate the freeze-dried antimicrobial agents. All of these steps were performed manually and took 5 minutes per sample. The panel was incubated at 35 C, and time-lapse imaging was performed three times at 0, 4 and 6 h after inoculation. After completing the image acquisition, automated image analysis was performed to determine MICs.
QMAC-dRAST with colony isolates
The isolated colonies were suspended in CAMHB to achieve a turbidity equivalent to that of a 0.5 McFarland standard. A 70 lL sample of the suspension was diluted with 4 mL of liquid state 0.5% agarose at 37-40 C. The subsequent procedure was the same as when using PBCB.
VITEK-2 AST and BMD test
AST using the VITEK-2 system was performed according to the manufacturer's protocol. The BMD test was performed as recommended by CLSI (Supplementary Materials and methods and Table S2 ). 12 
Resolution of discrepancies and data analysis
The QMAC-dRAST and VITEK-2 AST results were compared with the BMD results. The discrepant results were categorized as very major errors (VMEs), major errors (MEs) and minor errors (mEs). Agreement of interpretative results was calculated as previously described. 13 Isolates demonstrating VMEs or MEs were retested. If initial and repeated test results were not the same, the result of repeat testing was used for data analysis. The incubation time required to obtain final results was evaluated for the QMAC-dRAST and the VITEK-2 systems.
Results
Of the 110 isolates studied, 74 were staphylococci (39 Staphylococcus aureus and 35 CoNS) and 36 were enterococci (23 Enterococcus faecium and 13 Enterococcus faecalis). A total of 47 oxacillin-resistant staphylococci, 12 VRE and 10 linezolid-resistant strains were included (Table S3) .
AST results were available for all 110 isolates tested against 17 antimicrobial agents, resulting in 1461 AST measurements available for evaluation. The overall performances of the three test methods (the QMAC-dRAST with two types of inoculum and the VITEK-2 system) compared with that of the BMD are presented in Table 1 . The QMAC-dRAST with PBCB/colony isolates yielded 1.2%/1.0% VMEs, 4.3%/1.8% MEs and 5.4%/4.0% mEs, respectively. The VITEK-2 system yielded 2.3% VMEs, 0.5% MEs and 2.6% mEs. Overall agreements between each test method and the BMD test were all .90%. The VITEK-2 system showed the greatest agreement (96.2%) but the highest VME rate. The QMAC-dRAST system showed higher ME and mE rates compared with those for the VITEK-2 system.
The distribution of agreements and errors by individual antimicrobial agent is shown in Table 2 . Among 17 tested agents, only ampicillin and fusidic acid showed complete agreement (100%) in all three different methods. The QMAC-dRAST with PBCB yielded only mEs for levofloxacin, gentamicin and rifampicin, while VMEs and MEs were distributed among the majority of agents. In the QMAC-dRAST with colony isolates, vancomycin, levofloxacin, erythromycin, telithromycin, gentamicin and rifampicin showed only mEs. The majority of error rates, except mEs, were caused by a high rate of MEs for oxacillin and penicillin. Although the VITEK-2 system yielded overall good agreement, a higher rate of VMEs was noted for teicoplanin.
When the performance of each method was stratified by staphylococcal and enterococcal isolates (Tables S4 and S5) , agreements of the three test methods were all .90%, except for the QMAC-dRAST with PBCB for enterococci (88.3%). Huh et al. Table 2 .
Performance of the QMAC-dRAST and VITEK-2 systems compared with BMD for staphylococci and enterococci (n " Performance evaluation of the QMAC-dRAST
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The incubation time required to obtain final results was compared between the QMAC-dRAST and the VITEK-2 systems. Incubation time with the QMAC-dRAST was significantly shorter than with the VITEK-2 system (P , 0.0001). In the QMAC-dRAST, the incubation time was 6 h for all 110 isolates, regardless of inoculum type (PBCB or colony isolates). The median incubation time with the VITEK-2 system was 10 h (range 8-15 h).
Discussion
Recently, numerous studies have described rapid phenotypic AST using emerging technologies. [6] [7] [8] [14] [15] [16] [17] However, it remains to be determined whether these new technologies can achieve sufficient accuracy for use in routine clinical practice. Few studies have evaluated the clinical utility of these methods in comparison with conventional AST and reference methods. 14 Here we report the performance of the QMAC-dRAST with two types of inocula. The QMAC-dRAST method with PBCB has a wide dynamic range of inoculum sizes from PBCB without a separatory process; the previously reported methods for direct AST using PBCB require a bacteria-separating process such as centrifugation. 9, 18 Although the direct method using the QMAC-dRAST with PBCB yielded acceptable agreement (91.5%) and VME rate (1.2%), performance still needs to improve owing to a high ME rate (4.3%). Most MEs were detected for ciprofloxacin and trimethoprim/sulfamethoxazole. However, the QMAC-dRAST with colony isolates performed reliably, with 94.6% overall agreement, 1.0% VMEs, 1.8% MEs and 4.0% mEs. Therefore, the performance of the QMAC-dRAST with colony isolates met the criteria for acceptable accuracy of an AST method as outlined in the FDA guidelines (e.g. categorical agreement 90%, VMEs 1.5%, MEs 3%). 13, 19 Moreover, the QMAC-dRAST with colony isolates demonstrated equivalent performance to the VITEK-2 system, one of the most widely used AST methods. Conventional AST systems such as VITEK-2, MicroScan (Beckman Coulter Inc.) and Phoenix (Becton Dickinson Company) require averages of 9 h, 20 h and 10.5 h, respectively, from an isolated colony to final results, whereas the average time to AST results using the PBCB with a separatory process applied to the VITEK-2 Compact system was reported as 6.52 h. 4, 18 In this study, the QMAC-dRAST generated the final results after 6 h of incubation without variation, which was a remarkably reduced time compared with the VITEK-2 system (median 10 h). The QMAC-dRAST system can be a useful tool for rapid AST, although a skilled review of potential inaccuracies by a clinical microbiologist would be needed in order to guarantee the reliability of the results.
Potential shortcomings of this study include the limited number of some resistant phenotypes, such as to teicoplanin and linezolid. Also, the QMAC-dRAST was manually performed in our study because full automation of the QMAC-dRAST system was not available at the time of this study.
In conclusion, the QMAC-dRAST system provides rapid results and represents an alternative to conventional AST methods. The QMAC-dRAST system with colony isolates produced more reliable results for staphylococci and enterococci than the QMAC-dRAST with PBCB. It also performed comparably to BMD and the VITEK-2 system for AST. Therefore, the QMAC-dRAST system is expected to be a valuable AST tool in clinical microbiology laboratories.
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